Drug-drug interaction study between AT2220 and ERT

Registry ID

EUCTR2011-002154-32

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Amicus Therapeutics, Inc.

Start date

2011-11-04

Completion date

2013-01-04

Last update

2026-08-16

Conditions

• Pompe Disease

Summary

• To evaluate the safety of single ascending oral doses of AT2220 administered 1 hour before administration of alglucosidase alfa in patients with Pompe disease • To evaluate the effect of single ascending oral doses of AT2220 administered 1 hour before administration of a single intravenous infusion of alglucosidase alfa on the plasma pharmacokinetics of recombinant human acid alpha-glucosidase (rhGAA) in patients with Pompe disease

Locations

• , , UK

Related clinical trials

• Phrenic Nerve and Diaphragm Electrophysiology in Pompe Disease
• Pompe Disease Registry Protocol
• Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
• Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
• A Global Prospective Observational Registry of Patients With Pompe Disease
• Cognitive and Neurological Pathologies in Pompe Disease

View on source registry